Repligen (RGEN)

The company operates in specialized areas of bioprocessing, where manufacturers need reliable tools to grow, separate, purify, and monitor biological material at commercial quality standards. Filtration and fluid management form Repligen’s largest product category, reflecting demand for single-use systems, tangential flow filtration, and related processing components. It also sells chromatography products used in purification, proteins used in manufacturing workflows, and process analytics tools that help customers measure and control production.

Repligen’s business is global, with meaningful sales in North America, Europe, and Asia Pacific. Its customers range from large pharmaceutical companies to emerging biotech firms and CDMOs that manufacture medicines on behalf of drug developers. This gives the company exposure to the broader expansion of biologics manufacturing, outsourcing, and advanced therapy development, while also making its results sensitive to customer capital spending, inventory cycles, and clinical or commercial production demand.

What distinguishes Repligen is its focus on high-value niches within bioprocessing rather than drug discovery itself. The company does not depend on the success of a single therapy; instead, it sells enabling technologies used across many biologic production platforms. That positioning makes it a picks-and-shovels participant in the biopharma supply chain.